Articles related to OFF-LABEL USE

Claims that semaglutide microdosing works to maintain weight loss and manage blood sugar are mainly anecdotal and not backed by scientific research.

In the absence of contraindications, metformin should be seriously considered as an off-label initial therapy and as an adjunct to antiobesity medications approved by the US Food and Drug Administration.

“It isn’t easy to kick this… Because porn shrinks your world.” —Aline Zoldbrod, PhD

Adverse events from compounded semaglutide have led to hundreds of hospitalizations, highlighting critical safety concerns for healthcare providers managing patients seeking weight loss solutions.

GLP-1 receptor agonists, beyond their role in diabetes and obesity management, are showing promise in reducing alcohol cravings, potentially offering a novel approach to treating alcohol use disorder.

Recent studies indicate that while ketamine and ECT are equally effective for treating MDD, ketamine did not prove non-inferior to ECT for MDEs. Both treatments have distinct side effect profiles that are critical for clinical decision-making.